Dr. Tinglin Lu​ serves as a Partner at Genesis Capital, where he drives the firm’s biotech investment strategy and oversees end-to-end value creation across the portfolio. He has led investments in leading innovators, including Multitude Therapeutics, Nutshell Therapeutics, Catug Bio, AusperBio, Circode Biomed, AlphaGen and etc. Prior to joining Genesis Capital, Dr. Lu spent years in biopharmaceutical venture investment and business development at Northern Light Venture Capital and Simcere Pharmaceuticals. He holds both his Ph.D. and bachelor's degree in Biology from Tsinghua University.